论文部分内容阅读
特发性婴儿维生素 K 缺乏症时,血中可出现凝血酶原前体 PIVKA-Ⅱ,1984年 Howard 等报道,肝癌患者血中检测率明显增高。为此,作者按本原等方法,应用抗 PIVKA-Ⅱ单克隆抗体,经 ELISA 法对肝胆系统恶性肿瘤患者测定血 PIVKA-Ⅱ。作者收集了肝癌24例,胆管癌6例,转移性肝癌8例,肝硬化20例。PIVKA-Ⅱ>0.1(?)u/ml 为阳性。结果发现,PIVKA-Ⅱ阳性率肝癌为66.7%,胆管癌100%,转移性肝癌87.5%,肝硬化40%。为此,作者对肝癌和胆管癌作了进一步研究。肝癌:虽然维生素 K 吸收需胆汁存在,但 PIVKA-Ⅱ与黄疸间无明显相关性,且与肿瘤大小亦无关,而
When idiopathic infants have vitamin K deficiency, prothrombin precursor PIVKA-II may appear in blood. Howard et al. reported in 1984 that the detection rate of hepatocellular carcinoma patients was significantly higher. To this end, the authors used anti-PIVKA-II monoclonal antibodies and ELISA methods to measure blood PIVKA-II in patients with hepato-biliary malignancies according to the original method. The authors collected 24 cases of liver cancer, 6 cases of cholangiocarcinoma, 8 cases of metastatic liver cancer, and 20 cases of liver cirrhosis. PIVKA-II> 0.1 (?)u/ml is positive. The results showed that the positive rate of PIVKA-II was 66.7% for hepatocellular carcinoma, 100% for cholangiocarcinoma, 87.5% for metastatic liver cancer, and 40% for cirrhosis. To this end, the author made further studies on liver cancer and cholangiocarcinoma. Liver cancer: Although vitamin K absorption requires bile, there is no significant correlation between PIVKA-II and jaundice, and it has nothing to do with tumor size.